Ipsen to acquire Albireo for $952m.

Ipsen, a biopharmaceutical company, agreed to acquire Albireo, a biotechnology company, for $952m. “We are excited about the potential of Albireo’s assets and scientific expertise, which we gain through this acquisition, and we believe this is a compelling growth opportunity for Ipsen. Our Rare Disease franchise is strengthened with Bylvay, which, in addition to being the first-approved treatment in PFIC, has two further indications being investigated in rare liver conditions that are underserved. Additionally, Bylvay and the clinical and preclinical novel bile acid transport inhibitors in Albireo’s portfolio complement our own pipeline in liver disease," David Loew, Ipsen CEO.